Will mTOR inhibitors make it as cancer drugs?

By Sawyers C.L.  

Cancer Cell, Vol. 4, Iss. 5, 2003-11 ,pp. : 343-348

Elsevier

Access to resources Recommend Favorite

Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases

By Ladoire Sylvain   Beynat Caroline   Diaz Pierre   Coudert Bruno   Favier Laure   Ghiringhelli François  

Medical Oncology, Vol. 27, Iss. 3, 2010-09 ,pp. : 938-941

Humana Press, Inc

Access to resources Recommend Favorite

Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors

By Roca Sophie   Quivy Amandine   Gross-Goupil Marine   Bernhard Jean-Christophe   De Clermont Henri   Ravaud Alain  

Acta Oncologica, Vol. 50, Iss. 7, 2011-10 ,pp. : 1135-1136

Informa Healthcare

Access to resources Recommend Favorite

The Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in the Treatment of Solid Tumors

By  

Current Cancer Therapy Reviews, Vol. 4, Iss. 3, 2008-08 ,pp. : 227-234

Bentham Science Publishers

Access to resources Recommend Favorite

Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors

By Capdevila Jaume   Salazar Ramón   Halperín Irene   Abad Albert   Yao James  

Cancer and Metastasis Reviews, Vol. 30, Iss. 1, 2011-03 ,pp. : 27-34

Springer Publishing Company

Access to resources Recommend Favorite